These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23511629)

  • 1. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
    Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
    Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
    Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
    Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
    BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.
    Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Oncotarget; 2017 Jan; 8(1):1204-1212. PubMed ID: 27901483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
    Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
    Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; de la Taille A; Tourani JM; Bigot P; Linassier C; Négrier S; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
    Br J Cancer; 2013 Mar; 108(4):887-900. PubMed ID: 23462807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
    Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
    Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
    Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
    PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
    Motzer RJ; Escudier B; Bukowski R; Rini BI; Hutson TE; Barrios CH; Lin X; Fly K; Matczak E; Gore ME
    Br J Cancer; 2013 Jun; 108(12):2470-7. PubMed ID: 23695024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
    Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
    Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
    Diekstra MH; Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1477-84. PubMed ID: 26387812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
    Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
    Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.